Results 341 to 350 of about 191,621 (404)

The Duration of Proton Pump Inhibitor Therapy and the Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Khurmatullina AR, Andreev DN, Kucheryavyy YA, Sokolov FS, Beliy PA, Zaborovskiy AV, Maev IV.   +6 more
europepmc   +1 more source

Knowledge, Attitudes, and Practices of Community Pharmacists Regarding Proton Pump Inhibitor (PPI) Use: A Cross-Sectional Study. [PDF]

Healthcare (Basel)
Moustafa HAM, Al Meslamani AZ, Ahmed HMME, Ahmed SAF, Sallam NES, Alshehri GH, Alsubaie N, Kassem AB.   +7 more
europepmc   +1 more source

Dynamic Relevance Between Reflux Events and Esophageal Motility in Patients With Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. [PDF]

J Dig Dis
Lin SH, Wang ZF, Li H, Sun XH, Li XQ, Fei GJ, Chen WG, Guo T, Ke MY, Fang XC.   +9 more
europepmc   +1 more source

Pharmacodynamic Modelling of Irreversible and Reversible Gastric Proton Pump Inhibitors

, 2003
Angela Äbelö
openalex   +1 more source

Association between proton pump inhibitor use and migraine: a systematic review and meta-analysis. [PDF]

J Headache Pain
Satapathy P, Khatib MN, Vadia N, Menon SV, Chennakesavulu K, Panigrahi R, Shabil M, Singh M, Sah S, Lingamaiah D, Goh KW, Mawejje E, Bushi G.   +12 more
europepmc   +1 more source

Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?

Clinical Medicine Insights: Gastroenterology, 2012
Cheryl Durand, Kristine C. Willett, Alicia R. Desilets   +2 more
doaj  

Sex-specific Association of Chronic Proton Pump Inhibitor Use With Reduced Bone Density and Quality.

J Clin Endocrinol Metab
Bioletto F, Pusterla A, Fraire F, Sauro L, Presti M, Arvat E, Ghigo E, Procopio M, Barale M.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication

Alimentary Pharmacology and Therapeutics, 2022
One‐week triple therapy with vonoprazan is endorsed by Japanese guidelines as an alternative to proton pump inhibitor (PPI)‐based triple therapy for first‐line Helicobacter pylori eradication.
D. Ang, S. Koo, Y. Chan, T. Tan, G. Soon, C. K. Tan, K. Lin, Jaydeesh‐Khanna Krishnasamy‐Balasubramanian, Y. Wong, Rahul Kumar, Rajesh R, Y. Tan, Peng Lan Jeannie Ong, Y. Tan, J. W. Li, A. Kwek, T. Ang   +16 more
semanticscholar   +1 more source

Deprescribing proton pump inhibitors

Australian Journal of General Practice, 2022
Proton pump inhibitors (PPIs) are indicated for disorders including peptic ulcer disease and gastro-oesophageal reflux disease; however, they are often used for longer and at higher doses than recommended, or for indications that are not supported by evidence.The aim of this article is to outline evidence-based approaches to deprescribing PPIs.PPIs are
Turner, Justin P., Thompson, Wade, Reeve, Emily, Bell, J. Simon   +3 more
openaire   +4 more sources

Proton Pump Inhibitors

Annals of Pharmacotherapy, 2016
Objective: The purpose of this article is to describe the relationship between proton pump inhibitors (PPIs) and symptoms of myopathy based on case reports. Data Sources: A literature search was conducted in PubMed (1946 to June 2016) using MeSH terms proton pump inhibitors, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole ...
Evan W, Colmenares, Ashley L, Pappas
openaire   +3 more sources